Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Ankylosing spondylitis
Biologics
Observational
Psoriasis
Psoriatic arthritis
Real-world
Rheumatology
Safety
Secukinumab
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
20
02
2020
pubmed:
8
5
2020
medline:
23
2
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
Secukinumab, a fully human monoclonal antibody that directly inhibits interleukin-17A, has demonstrated robust efficacy in the treatment of moderate to severe psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a rapid onset of action, sustained long-term clinical responses and a consistently favourable safety profile across phase 3 trials. Here, we report the clinical data at enrolment from SERENA, designed to investigate the real-world use of secukinumab across all three indications. SERENA is an ongoing, longitudinal, observational study conducted at 438 sites across Europe in patients with moderate to severe plaque PsO, active PsA or active AS. Patients should have received at least 16 weeks of secukinumab treatment before enrolment in the study. Overall 2800 patients were included in the safety set; patients with PsA (N = 541) were older than patients with PsO (N = 1799) and patients with AS (N = 460); patients with PsO had a higher mean body weight than patients with PsA and patients with AS; and patients with PsO and patients with AS were predominantly male. Time since diagnosis was longer in patients with PsO compared with patients with PsA and patients with AS, and about 40% of patients were either current or former smokers. The proportion of obese patients (body mass index ≥ 30 kg/m Baseline demographics of the study population are consistent with existing literature. This large observational study across all secukinumab indications will provide valuable information on the long-term effectiveness and safety of secukinumab in the real-world setting.
Identifiants
pubmed: 32378070
doi: 10.1007/s12325-020-01352-8
pii: 10.1007/s12325-020-01352-8
pmc: PMC7467439
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2865-2883Références
Schreiber S, Colombel J-F, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78(4):473–9.
pubmed: 30674475
pmcid: 6530077
doi: 10.1136/annrheumdis-2018-214273
Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7–32.
Turkiewicz AM, Moreland LW. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum. 2007;56(4):1051–66.
pubmed: 17393414
doi: 10.1002/art.22489
Zeng J, Luo S, Huang Y, Lu Q. Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol. 2017;44(8):863–72.
pubmed: 28349593
doi: 10.1111/1346-8138.13806
Avaloz-Diaz E, Dominguez-Cherit J, Herrera-Esparza R. Cutaneous manifestations of spondyloarthritis. Int J Clin Rheumatol. 2012;7(1):55–61.
doi: 10.2217/ijr.11.64
Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213–20.
pubmed: 27739123
doi: 10.1111/jdv.14007
Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–7.
pubmed: 23425140
doi: 10.1111/jdv.12106
Wervers K, Luime JJ, Tchetverikov I, et al. Influence of disease manifestations on health-related quality of life in early psoriatic arthritis. J Rheumatol. 2018;45(11):1526–31.
pubmed: 29961685
doi: 10.3899/jrheum.171406
Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):857–72.
pubmed: 25193010
doi: 10.1586/14737167.2014.957679
Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–94.
pubmed: 26025581
doi: 10.1016/S0140-6736(14)61909-7
Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Dermato-venereol. 2010;90(2):147–51.
doi: 10.2340/00015555-0770
von Stebut E, Reich K, Thaci D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–62.
doi: 10.1016/j.jid.2018.10.042
Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009;23(5):561–5.
pubmed: 19207663
doi: 10.1111/j.1468-3083.2008.03031.x
Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):677–98.
doi: 10.1016/j.rdc.2015.07.008
Molto A, Dougados M. Comorbidities in spondyloarthritis including psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):390–400.
pubmed: 31171310
doi: 10.1016/j.berh.2018.09.002
Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197–204.
pubmed: 12686053
doi: 10.1016/S0140-6736(03)12954-6
Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49(2):271–5.
pubmed: 12894076
doi: 10.1067/S0190-9622(03)01479-8
Radtke MA, Langenbruch AK, Schafer I, Herberger K, Reich K, Augustin M. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas. 2011;2:1–6.
pubmed: 22915964
Menter A. Psoriasis and psoriatic arthritis overview. Am J Managed Care. 2016;22(8 Suppl):s216–s224224.
Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of genital psoriasis: a systematic review. Dermatol Ther (Heidelb). 2018;8(4):509–25.
doi: 10.1007/s13555-018-0257-y
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85.
pubmed: 23014338
doi: 10.1038/jid.2012.339
Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–65.e19.
pubmed: 29928910
doi: 10.1016/j.jaad.2018.06.027
Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736–40.
pubmed: 22730367
doi: 10.1136/annrheumdis-2012-201706
European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. EMA. 2004. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf . Accessed 12 Feb 2020.
Ryan C, Korman NJ, Gelfand JM, et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014;70(1):146–67.
pubmed: 24126079
doi: 10.1016/j.jaad.2013.08.042
Chiricozzi A, Balato A, Conrad C, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatol Treat. 2019:1–8. https://doi.org/10.1080/09546634.2019.1671577 .
Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of Spondyloarthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheumatic Dis. 2009;68(Suppl 2):ii1–44.
doi: 10.1136/ard.2008.104018
Garg N, van den Bosch F, Deodhar A. The concept of spondyloarthritis: where are we now? Best Pract Res Clin Rheumatol. 2014;28(5):663–72.
pubmed: 25488776
doi: 10.1016/j.berh.2014.10.007
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–733.
pubmed: 16871531
pmcid: 16871531
doi: 10.1002/art.21972
Belasco J, Wei N. Psoriatic arthritis: what is happening at the joint? Rheumatol Ther. 2019;6(3):305–15.
pubmed: 31102105
pmcid: 6702660
doi: 10.1007/s40744-019-0159-1
Olivieri I, D'Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014;10(9):531–42.
pubmed: 25003762
doi: 10.1038/nrrheum.2014.106
Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ. 2012;15(6):1054–63.
pubmed: 22563743
doi: 10.3111/13696998.2012.692341
Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65–73.
doi: 10.1136/annrheumdis-2013-203582
pubmed: 23999006
Mielants H, Van den Bosch F. Extra-articular manifestations. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S56–61.
pubmed: 19822047
Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford). 2009;48(9):1029–35.
doi: 10.1093/rheumatology/kep146
Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650–7.
doi: 10.1093/rheumatology/ket387
Ivanov S, Linden A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci. 2009;30(2):95–103.
pubmed: 19162337
doi: 10.1016/j.tips.2008.11.004
Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discovery. 2012;11(10):763–76.
pubmed: 23023676
doi: 10.1038/nrd3794
Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–50.
pubmed: 24655820
doi: 10.1016/j.jaad.2013.12.036
Keijsers RR, Joosten I, van Erp PE, Koenen HJ, van de Kerkhof PC. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol. 2014;23(11):799–803.
pubmed: 25039885
doi: 10.1111/exd.12487
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
pubmed: 19641206
doi: 10.1056/NEJMra0804595
Braun T, Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):235.
pubmed: 21861862
pmcid: 3239343
doi: 10.1186/ar3380
Maruotti N, Grano M, Colucci S, d'Onofrio F, Cantatore FP. Osteoclastogenesis and arthritis. Clin Exp Med. 2011;11(3):137–45.
pubmed: 21069419
doi: 10.1007/s10238-010-0117-2
Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med. 2012;18(7):1018–9.
pubmed: 22772553
doi: 10.1038/nm.2854
Louie GH, Ward MM. Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials. Curr Opin Rheumatol. 2014;26(2):145–50.
pubmed: 24389865
pmcid: 4209248
doi: 10.1097/BOR.0000000000000025
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.
pubmed: 25007392
doi: 10.1056/NEJMoa1314258
McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46.
pubmed: 26135703
doi: 10.1016/S0140-6736(15)61134-5
Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–13.
pubmed: 24035250
doi: 10.1016/S0140-6736(13)61134-4
Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–14.
pubmed: 29444376
pmcid: 6175198
doi: 10.1111/jdv.14878
Langley RG, Sigurgeirsson B, Szepietowski JC, et al. Secukinumab maintains improvements in psoriasis through five years of treatment: a randomized extension of the phase III ERASURE and FIXTURE trials. Oral presentation at American Academy of Dermatology (AAD) Annual Meeting, Mar 1–5, 2019, Washington D.C., USA.
McInnes IB, Kivitz AJ, Nash P, et al. Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: long-term (4-year) data from a phase 3 study. Poster presented at The American College of Rheumatology (ACR) Annual Meeting, October 19–24, 2018, Chicago, USA.
Marzo-Ortega H, Sieper J, Kivitz AJ, et al. Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with consistent safety profile and high retention rate: 4-year results from a phase III trial. Poster presented at The American College of Rheumatology (ACR) Annual Meeting, October 19–24, 2018, Chicago, USA.
Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–74.
pubmed: 30357570
pmcid: 6223979
doi: 10.1007/s12325-018-0805-y
Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthcare. 2018;11:295–304.
doi: 10.2147/JMDH.S160029
Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33(34):e213.
pubmed: 30127705
pmcid: 6097073
doi: 10.3346/jkms.2018.33.e213
COSENTYX [Summary of Product Characteristics]. Camberley, UK: Novartis Europharm Limited. 2019.
Korber A, Thaci D, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, et al. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. J Eur Acad Dermatol Venereol. 2018;32(3):411–9.
pubmed: 28960469
doi: 10.1111/jdv.14604
Thaci D, Korber A, von Kiedrowski R, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatol Venereol. 2020;34:310–8.
pubmed: 31541554
doi: 10.1111/jdv.15962
Kiltz U, Legeler C, Maier-Peuschel M, Mann C, Tony H-P. Baseline characteristics of patients with ankylosing spondylitis and psoriatic arthritis treated with secukinumab in the real-world setting: AQUILA, a non-interventional study. Open Rheumatol J. 2019;13:53–60.
doi: 10.2174/1874312901913010053
Papp KA, Gooderham M, Beecker J, et al. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America. BMC Dermatol. 2019;19(1):9.
pubmed: 31226985
pmcid: 6588885
doi: 10.1186/s12895-019-0087-3
Mann HF, Zavada J, Senolt L, et al. Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. Clin Exp Rheumatol. 2019;37(2):342–3.
pubmed: 30620295
Strober BE, Germino R, Guana A, et al. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. J Dermatol Treat. 2019;1–9. https://doi.org/10.1080/09546634.2019.1603361
pubmed: 31035822
doi: 10.1080/09546634.2019.1603361
Blauvelt A, Reich K, Tsai T-F, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60–9.e9.
pubmed: 27663079
doi: 10.1016/j.jaad.2016.08.008
Mease P, van der Heijde D, Landewe R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890–7.
pubmed: 29550766
pmcid: 5965348
Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatol Treat. 2003;14(3):158–65.
doi: 10.1080/09546630310013360
Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861–7.
pubmed: 15888138
doi: 10.1111/j.1365-2133.2005.06502.x
Gladman DD, Mease PJ, Krueger G, et al. Outcome measures in psoriatic arthritis. J Rheumatol. 2005;32(11):2262–9.
pubmed: 16265714
Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 2011;63(S11):S64–S85.
doi: 10.1002/acr.20577
Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. 2011;63(S11):S240–S252252.
doi: 10.1002/acr.20543
Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686–91.
pubmed: 18438903
doi: 10.1002/art.23568
Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res. 2011;63(S11):S47–S58.
doi: 10.1002/acr.20575
Machado PMMC, Landewé RBM, van der Heijde DM. Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. J Rheumatol. 2011;38(7):1502–6.
pubmed: 21724723
doi: 10.3899/jrheum.110279
Knop C, Oeser M, Bastian L, Lange U, Zdichavsky M, Blauth M. Development and validation of the Visual Analogue Scale (VAS) Spine Score. Unfallchirurg. 2001;104(6):488–97.
pubmed: 11460453
doi: 10.1007/s001130170111
Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheumatic Dis. 2003;62(2):127–32.
doi: 10.1136/ard.62.2.127
Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–48.
pubmed: 26699169
doi: 10.1056/NEJMoa1505066
Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–39.
pubmed: 26422723
doi: 10.1056/NEJMoa1412679
Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–93.
pubmed: 25132411
doi: 10.1111/bjd.13348
Lacour JP, Paul C, Jazayeri S, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 2017;31(5):847–56.
pubmed: 28111801
doi: 10.1111/jdv.14073
Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–90.
pubmed: 25243910
doi: 10.1111/jdv.12751
Bonomo L, Abittan BJ, Hashim PW, Karki C, Mason M, Lebwohl M. Combination use of systemic therapies in psoriasis: baseline characteristics from the Corrona Psoriasis Registry. J Drugs Dermatol. 2019;18(8):731–40.
pubmed: 31424705
Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019;5(1):e000880.
pubmed: 31168408
pmcid: 6525627
doi: 10.1136/rmdopen-2018-000880
Mease PJ, Karki C, Liu M, et al. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. RMD Open. 2018;4(1):e000638.
pubmed: 29707232
pmcid: 5916237
doi: 10.1136/rmdopen-2017-000638